Ponatinib is a first-generation targeted drug

Ponatinib (Ponatinib) is a third-generation kinase inhibitor designed to overcome the T315I mutation. In separate trials, the drug showed inhibitory activity against native BCR-ABL1 kinase and several ABL1 mutations. For this reason, ponatinib is currently used to treat chronic myeloid leukemia (CML) that is resistant and/or intolerant to dasatinib and nilotinib, as well as patients for whom imatinib is no longer suitable or patients with T315I mutations.

Leukemia is a malignant tumor of the hematopoietic system. With a better understanding of its pathogenesis, third-generation tyrosine kinase inhibitors (TKIs) have been developed. Ponatinib is a third-generation breakpoint cluster (BCR) and Abelson (ABL) TKI, which are influential in the treatment of leukemia. This medicine is available as an oral tablet. Patients usually take ponatinib once a day, with or without food, at approximately the same time each day.

The original drug of Ponatinib has not yet been launched in China, so it is not included in the medical insurance. Domestic patients in need may only purchase it through overseas channels. The Hong Kong original version of Ponatinib specificationsThe price of 45mg*30 tablets per box may be around 40,000 yuan (the price may fluctuate due to the exchange rate), which is expensive. There are also generic ponatinib drugs produced in other countries, which are relatively cheap. The price of 45mg*30 tablets per box produced by Everest Pharmaceutical Factory in Bangladesh may be around 4,000 yuan (the price may fluctuate due to the exchange rate), and its drug ingredients are basically the same as those of the original drug.